Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Stroma cells: a novel target of herceptin activity.

Corsini C, Mancuso P, Paul S, Burlini A, Martinelli G, Pruneri G, Bertolini F.

Clin Cancer Res. 2003 May;9(5):1820-5.

2.

CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.

Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G.

Cancer Res. 2002 Jun 1;62(11):3106-12.

3.

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.

Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cinieri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G.

Ann Oncol. 2001 Jul;12(7):987-90. Erratum in: Ann Oncol 2001 Sep;12(9):1333. Cineri S [corrected to Cinieri S].

4.

Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.

Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F.

Cancer Res. 2001 Jun 1;61(11):4341-4.

5.

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients.

Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F.

Blood. 2001 Jun 1;97(11):3658-61.

PMID:
11369666
6.

Use of IgM monoclonal reagents licensed for tube tests in column agglutination technology.

Morelati F, Burlini A, Reis KJ, Drago F, Revelli N, Villa MA, Guffanti A, Italiano Z, Parravicini A, Rebulla P, Sirchia G.

Transfusion. 1998 Nov-Dec;38(11-12):1037-40.

PMID:
9838934

Supplemental Content

Loading ...
Support Center